TherapyCaliforniaOwned by therapists
For therapistsFor schools & counties
California psychedelic claim checker · updated August 31, 2026

A claim can borrow a white coat.

The record still needs a number.

Choose the exact substance. Choose the exact claim. See what the document can carry—and what it cannot.

California legal and licensed-prescriber review are pending. This tool does not decide whether a person, program, church, sale or study is lawful, safe, effective or appropriate for you. No review badge is claimed.

Two exact choices

Make the sentence name its parts.

“Psychedelic medicine” is too vague. So are “approved,” “licensed,” and “research-backed” until they point to a product, use, person, place and record.

Your two choices stay in this browser tab. There is no free-text field. The tool does not send, save, score or diagnose your choices.

No verdict is being made

Choose both fields.

The checker needs an exact substance and an exact claim before it can show the record boundary.

Scan all 17 lanes

The same bright word is hiding different systems.

Official-source snapshot updated August 31, 2026. Research counts are ingredient-family buckets, not claims about a brand, formulation or route. They include open, active-closed, status-unknown and suspended records and do not imply access or effectiveness.
Substance or productFederal mental-health laneCalifornia laneCurrent California research snapshot
Esketamine nasal spray (Spravato)Specific FDA-approved adult usesExisting medical-licensing lane; no separate psychedelic-facilitator licence.The dated California desk tracks 4 esketamine records; the registry ingredient name does not establish that every protocol uses branded Spravato. Study type and enrollment status vary.
FDA-approved ketamine injection (IV or IM)Approved anesthetic · psychiatric use off-labelExisting medical-licensing lane; psychiatric use is off-label.The dated California desk tracks 13 ketamine-containing records; formulation, route and study purpose vary. Study type and enrollment status vary.
Compounded ketamineCompounded product · not FDA approvedMedical and compounding rules; the product is not FDA approved.Registry records are classified by ingredient and protocol, not by whether a dispensed product was compounded.
Psilocybin or psilocin (not analogs)Investigational · no statewide California service system identified in this reviewNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 25 psilocybin or psilocin records; combination protocols may also appear. Study type and enrollment status vary.
CYB003 (synthetic psilocin analog)Investigational analog · California Phase 3 researchNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 3 CYB003 records. Study type and enrollment status vary.
RE104Investigational sponsor-coded compound · California researchNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 2 RE104 records. Study type and enrollment status vary.
(2R,6R)-Hydroxynorketamine (RR-HNK)Investigational ketamine metabolite · California researchNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 1 RR-HNK or hydroxynorketamine records. Study type and enrollment status vary.
MDMA / midomafetamineInvestigational · not FDA approved for PTSDNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 5 MDMA records. Study type and enrollment status vary.
LSD / lysergideInvestigational · California Phase 3 researchNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 4 LSD or lysergide records. Study type and enrollment status vary.
Methylone / TSND-201Investigational entactogen · not MDMANo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 1 methylone records. Study type and enrollment status vary.
DMTInvestigational · California mechanism researchNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 1 DMT records; 5-MeO-DMT and ayahuasca are separate lanes. Study type and enrollment status vary.
5-MeO-DMTInvestigational · no open California treatment route foundNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 1 records that name 5-MeO-DMT; the tracked record is a mixed-substance observational protocol. Study type and enrollment status vary.
AyahuascaNo FDA-approved use · no statewide California service system identified in this reviewNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks no record in this substance lane. That is a zero in this dataset, not proof that no research exists.
Mescaline (the chemical)No FDA-approved use · no open California treatment study foundNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks no record in this substance lane. That is a zero in this dataset, not proof that no research exists.
PeyoteControlled substance · narrow federal religious-use ruleNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks no record in this substance lane. That is a zero in this dataset, not proof that no research exists.
IbogaineInvestigational · California records are observationalNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks 3 ibogaine records; mixed-substance protocols may also appear. Study type and enrollment status vary.
NoribogaineEarly research allowed to proceed · not approvedNo statewide licensed-service system identified in the dated official-source review; legal review pending.The dated California desk tracks no record in this substance lane. That is a zero in this dataset, not proof that no research exists.
Five records beat one adjective

Ask the claim to show its papers.

  1. Drug recordThe current FDA label or Drugs@FDA entry—not a press release.
  2. Research recordThe NCT number, study type, exact California site and local status.
  3. Professional recordEach California licence, verified at the board that issued it.
  4. Supply recordThe manufacturer, pharmacy, compounder, lot or study source behind the actual product.
  5. Authority claimedThe exact statute, agency licence, exemption or court order—and what conduct it covers.
Keep the lanes separate

A clinic, a trial and a ceremony are not synonyms.

The next tool depends on the decision you are actually making. The trial desk reads sponsor-posted California records. The consent checklist examines screening, medicines, touch, monitoring, cost and follow-up before you pay or enroll.

Use the California clinical-trial desk →Use the safety and consent checklist →Return to the treatment decision map →
Source ledger

The documents behind the answers.

  1. FDA Drugs@FDA database. U.S. Food and Drug Administration · checked 2026-09-04
  2. FDA Spravato prescribing information, revised 2025. U.S. Food and Drug Administration · revised 2025-04-01 · checked 2026-09-04
  3. FDA: Understanding Unapproved Use of Approved Drugs “Off Label”. U.S. Food and Drug Administration · revised 2018-02-05 · checked 2026-09-04
  4. FDA: Understanding the Current Use of Ketamine. U.S. Food and Drug Administration · published 2024-06-27 · checked 2026-09-04
  5. FDA Ketalar prescribing information. U.S. Food and Drug Administration · revised 2025-10-01 · checked 2026-09-04
  6. FDA: Compounding and FDA Questions and Answers. U.S. Food and Drug Administration · revised 2025-09-16 · checked 2026-09-04
  7. FDA compounded-drug risk alerts. U.S. Food and Drug Administration · revised 2026-08-27 · checked 2026-09-04
  8. FDA final psychedelic-drug clinical-investigation guidance, July 2026. U.S. Food and Drug Administration · published 2026-07 · checked 2026-09-04
  9. FDA April 2026 noribogaine IND announcement. U.S. Food and Drug Administration · published 2026-04-24 · checked 2026-09-04
  10. California Health and Safety Code §11054. California Legislative Information
  11. California Health and Safety Code §11056. California Legislative Information
  12. California Health and Safety Code §11213. California Legislative Information
  13. California DOJ Research Advisory Panel. California Department of Justice, Office of the Attorney General · revised 2026-07-10 · checked 2026-09-04
  14. 21 CFR §1308.11: federal Schedule I list. Office of the Federal Register
  15. 21 CFR §1308.13: federal Schedule III list. Office of the Federal Register
  16. California governor’s SB 58 veto message. Office of the Governor of California · published 2023-10-07 · checked 2026-09-04
  17. DEA religious-exemption petition guidance. U.S. Drug Enforcement Administration · published 2020-11-20 · checked 2026-09-04
  18. 21 CFR §1307.31: Native American Church peyote rule. Office of the Federal Register · revised 2017-01-03 · checked 2026-09-04
  19. Primary Phase 3 MDMA-assisted-therapy trial report. Nature Medicine · published 2023-10 · checked 2026-09-04
  20. ClinicalTrials.gov disclaimer. U.S. National Library of Medicine
  21. ClinicalTrials.gov: Learn About Studies. U.S. National Library of Medicine
  22. California Department of Consumer Affairs licence search. California Department of Consumer Affairs · checked 2026-09-04

The reasoning below each answer was reviewed August 31, 2026. Every document in the ledger now carries its own dates: the date its publisher last revised it, and the day a person here opened it. Some show neither because the publisher states no date, and a few show no check date because the publisher does not let an automated client read the page; those are confirmed by hand. “No system identified” means none appeared in this dated official-source review; it is not a universal legal conclusion. California legal and licensed-prescriber review are pending. Paid for by participating therapists. Inclusion is computed, never purchased. No ads. No data sold.